enGene Therapeutics (ENGN) Capital Expenditures (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Capital Expenditures data on file, last reported at $98000.0 in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 117.78% year-over-year to $98000.0; the trailing twelve-month figure through Jul 2026 stood at $688000.0 (down 46.5% YoY), and the FY2025 full-year result was $1.5 million, up 60.54% from the prior year.
• Capital Expenditures was $98000.0 for Q2 2026 at enGene Therapeutics, down from $153000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $704000.0 in Q3 2025 to a low of $2000.0 in Q3 2024.
• A 4-year average of $212785.7 and a median of $155000.0 in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures tumbled 98.73% in 2024 and soared 35100.0% in 2025, its largest moves.
• enGene Therapeutics' Capital Expenditures stood at $138000.0 in 2023, then soared by 72.46% to $238000.0 in 2024, then surged by 83.61% to $437000.0 in 2025, then tumbled by 77.57% to $98000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $98000.0 in Q2 2026, $153000.0 in Q1 2026, and $437000.0 in Q4 2025.